Abstract
IntroductionThe albumin-bilirubin (ALBI) score, a new model for assessing severity of liver dysfunction was initially used in hepatocellular carcinoma but has not been thoroughly investigated in ACLF. The aim of this study was to assess prognostic value of ALBI score for predicting 28 days mortality in Sudanese patients with ACLF.MethodsThis cross-sectional study included 34 patients diagnosed as ACLF using APASL criteria for diagnosis. The etiology of the underlying chronic liver disease and precipitating cause of ACLF were investigated and ALBI, MELD and CTP scores were calculated within 24 hours of admission. Mortality was assessed during hospital stay and if discharged at 28 days post enrollment by telephone conversation. Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS 2.0).ResultsALBI scores were significantly associated with 28-days outcome as the mean of ALBI in the non-survived patients was higher than in the survived (-0.45±0.39 vs -0.65±0.59; P. value = 0.004). Regarding the predictive performances of the ALBI, MELD and CTP scores in detecting the 28-days mortality, ROC analysis showed that the AUC of MELD was 0.746 (95% CI: 0.575-0.916; P. value= 0.015), ALBI was 0.700 (95% CI: 0.512-0.888; P. value= 0.048), and CTP was 0.533 (95% CI: 0.334-0.733; P. value= 0.742).Abstract PWE-8 Figure 1The multiple receiver operating characteristic curve (ROC) to evaluate validity of MELD, ALBI and CTP in detecting the 28-days mortalityConclusionA higher ALBI score measured at admission is a useful predictor of 28 day mortality in ACLF patients. ALBI score was comparable to MELD and did better than CTP scores in predicting short-term mortality in these patients.